MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ
252.80
-6.68
-2.57%
After Hours: 252.77 -0.03 -0.01% 18:06 02/03 EST
OPEN
259.23
PREV CLOSE
259.48
HIGH
262.77
LOW
252.30
VOLUME
500.78K
TURNOVER
0
52 WEEK HIGH
283.09
52 WEEK LOW
158.38
MARKET CAP
11.52B
P/E (TTM)
17.20
1D
5D
1M
3M
1Y
5Y
Reported Earlier, Patent Trial And Appeal Board Reaffirms Decision To Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ('793 Patent)
Benzinga · 2d ago
Liquidia gains after PTAB denies United Therapeutics request for rehearing patent
Seeking Alpha · 2d ago
The PTAB Denies United Therapeutics Request For A Rehearing Of The $UTHR '793 Patent Invalidation Decision
Benzinga · 2d ago
--UBS Adjusts United Therapeutics' Price Target to $330 From $320, Maintains Buy Rating
--UBS Adjusts United Therapeutics' Price Target to $330 From $320, Maintains Buy Rating
MT Newswires · 3d ago
Insider Sell: United Therapeutics
Insider Sell: United Therapeutics
MT Newswires · 5d ago
United Therapeutics (UTHR) Presents At 41st Annual Healthcare Conference - Slideshow
Seeking Alpha · 01/20 12:49
Analyst Ratings for United Therapeutics
Benzinga · 01/11 14:01
Argus Research Maintains Buy on United Therapeutics, Raises Price Target to $300
Benzinga · 01/11 13:10
More
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). It also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.

Webull offers kinds of United Therapeutics Corporation stock information, including NASDAQ:UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.